Chemomab Therapeutics (CMMB) Interest Expenses (2018 - 2025)
Chemomab Therapeutics (CMMB) posted Interest Expenses of $49.9 million for Q4 2025, up 12.75% on a QoQ basis from $44.2 million in Q4 2024, and up 12.75% year-over-year from $44.2 million in Q4 2024.
Chemomab Therapeutics (CMMB) Interest Expenses (2018 - 2025) Analysis & Trends
Chemomab Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $49.9 million for Q4 2025.
- Quarterly Interest Expenses rose 12.75% year-over-year to $49.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.9 million (up 12.75% YoY) and the FY2025 annual result came in at $49.9 million, up 12.75% from the prior year.
- Interest Expenses was $49.9 million for Q4 2025 at Chemomab Therapeutics, up from $44.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $49.9 million in Q4 2025 and bottomed at $36.0 million in Q4 2021.
- A 5-year average of $43.0 million and a median of $43.5 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses jumped 14487.04% — and 2024, when it climbed 1.72%.
- Chemomab Therapeutics' Interest Expenses stood at $36.0 million in 2021, then increased by 14.34% to $41.2 million in 2022, then rose by 5.52% to $43.5 million in 2023, then grew by 1.72% to $44.2 million in 2024, then climbed by 12.75% to $49.9 million in 2025.
- Business Quant data shows CMMB's Interest Expenses at $49.9 million in Q4 2025, $44.2 million in Q4 2024, and $43.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | 49.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.86 Mn |
| Dec 31, 2025 | 49.86 Mn |
| Dec 31, 2024 | 44.22 Mn |
| Dec 31, 2024 | 44.22 Mn |
| Dec 31, 2023 | 43.47 Mn |
| Dec 31, 2023 | 43.47 Mn |
| Dec 31, 2022 | 41.20 Mn |
| Dec 31, 2022 | 41.20 Mn |
| Dec 31, 2021 | 36.03 Mn |
| Dec 31, 2021 | 36.03 Mn |
| Dec 31, 2020 | 247,000.00 |
| Dec 31, 2020 | 247,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Sep 30, 2019 | 12.58 Mn |
| Sep 30, 2019 | 12.58 Mn |
| Jun 30, 2019 | 18,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Mar 31, 2019 | 22,000.00 |